麗珠集團(000513.SZ):注射用伏立康唑及注射用頭孢地嗪鈉擬中選第八批全國藥品集採
格隆匯3月31日丨麗珠集團(000513.SZ)公佈,近日,公司參加了聯合採購辦公室組織的第八批全國藥品集中採購。公司注射用伏立康唑及注射用頭孢地嗪鈉擬中選該次集中採購。
注射用伏立康唑主要用於進展性、可能威脅生命的真菌感染患者的治療,可用於預防接受異基因造血幹細胞移植(HSCT)的高危患者的侵襲性真菌感染。適用於治療成人和2歲及2歲以上兒童患者的下列真菌感染:(1)侵襲性麴黴病。(2)非中性粒細胞減少患者的念珠菌血症。(3)對氟康唑耐藥的念珠菌引起的嚴重侵襲性感染(包括克柔念珠菌)。(4)由足放線病菌屬和鐮刀菌屬引起的嚴重感染。注射用伏立康唑已於2023年1月獲批註冊生產(視同通過一致性評價),2022年度銷售收入約為人民幣2.37億元,約佔公司2022年度營業收入的1.88%。
注射用頭孢地嗪鈉用於敏感菌引起的感染,如上、下泌尿道感染,下呼吸道感染,淋病等。注射用頭孢地嗪鈉已於2022年7月通過一致性評價,2022年度銷售收入約為人民幣2697.07萬元,約佔公司2022年度營業收入的0.21%。
該次擬中選產品價格與原價相比有所下降。若確定中選、簽訂購銷合同並實施後,將有利於上述產品快速打開國內銷售市場,提高市場佔有率,促進公司製劑業務的進一步發展,提升公司的品牌影響力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.